Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.98 |
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.78 |
| ▸ | PKM | P14618 | 2/20 | 0.78 |
| ▸ | APEX1 | P27695 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.67 |
| ▸ | CTSB | P07858 | 1/20 | 0.67 |
| ▸ | ELANE | P08246 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282468 | 0.99 | AKT1 (1.00) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL11893071 | 0.99 | AKT1 (1.00) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL11893069 | 0.92 | AKT1 (1.00) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL282462 | 0.92 | AKT1 (1.00) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL283620 | 0.90 | AKT1 (0.83) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL11891694 | 0.89 | AKT1 (0.81) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL11893078 | 0.88 | AKT1 (0.80) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL282503 | 0.87 | AKT1 (1.00) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL283324 | 0.86 | AKT1 (0.77) | AKT1MEN1KMT2APKMAPEX1 | |
| SCHEMBL328581 | 0.84 | AKT1 (0.76) | AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | claimed |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | AKT3, AKT1, AKT2 | AKT1 2/4885MEN1 2953/4885KMT2A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.